Competitive engraftment of primary cord blood and adult bone marrow CD34+ cells in triple HLA-mismatched SCID-hu bone model
| Population* . | No. of cells injected per bone† . | ABM positive grafts‡ . | Primary ABM % positive cells1-153 . | CB positive grafts‡ . | Primary CB % positive cells1-153 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| CD34+ . | CD34+CD38− . | CD33 . | CD19 . | CD34 . | CD33 . | CD19 . | CD34 . | |||
| ABM | 9 × 104 | 1.14 × 103 | 5/6 | 29 ± 13 | 49 ± 19 | 47 ± 18 | ||||
| CB | 9 × 104 | 1.13 × 103 | 6/6 | 31 ± 9 | 30 ± 13 | 36 ± 10 | ||||
| ABM + CB | See above | 5/10 | 3.6 ± 1.6 | 5.8 ± 1.7 | 4.1 ± 1.3 | 10/10 | 36 ± 5 | 30 ± 5 | 27 ± 7 | |
| Population* . | No. of cells injected per bone† . | ABM positive grafts‡ . | Primary ABM % positive cells1-153 . | CB positive grafts‡ . | Primary CB % positive cells1-153 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| CD34+ . | CD34+CD38− . | CD33 . | CD19 . | CD34 . | CD33 . | CD19 . | CD34 . | |||
| ABM | 9 × 104 | 1.14 × 103 | 5/6 | 29 ± 13 | 49 ± 19 | 47 ± 18 | ||||
| CB | 9 × 104 | 1.13 × 103 | 6/6 | 31 ± 9 | 30 ± 13 | 36 ± 10 | ||||
| ABM + CB | See above | 5/10 | 3.6 ± 1.6 | 5.8 ± 1.7 | 4.1 ± 1.3 | 10/10 | 36 ± 5 | 30 ± 5 | 27 ± 7 | |
ABM indicates adult bone marrow; CB, cord blood.
HLA-mismatched immunomagnetically selected CD34+ ABM and CB cells were injected individually or simultaneously into human fetal bone fragment (bearing a third distinct HLA allele) implanted in the SCID mouse (SCID-hu bone assay) to determine their competitive marrow repopulating ability.
Ten weeks after injection, fetal bone implants were removed and analyzed for the presence of ABM and CB HLA-bearing cells and CD19, CD33, and CD34 cells in a 5-color flow-cytometric assay. Uninjected grafts were used to determine the level of nonspecific binding of monoclonal antibodies.
Positive grafts indicate number of grafts containing donor-derived multilineage hematopoiesis per total number of injected grafts.
Percent positive cells represent donor-derived to total cells of the particular cell lineage present in the bone 10 weeks after injection. Numbers are expressed as mean % ± SEM.